Ruchika Bhasin, MD
Internal Medicine · Northridge
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 22 years
- Graduated 2004
Offices
1 location · Renal Consultants Medical Group · 9 clinicians in this group
Looking this up.
Hospitals listed: 052827 · 552853 · Los Robles Hospital & Medical Center · Northridge Hospital Medical Center · UCLA West Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bhasin’s office at (818) 349-1262 to ask if they take your plan before you enroll.
California Medical Board record
Licence A112947 · Current
Licensed to practise in California · since 2010 · expires 2028-04-30 · Manipal Academy of Higher Education Kasturba Medical College Mangalore.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Nephrology
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Los Robles Hospital & Medical CenterThousand Oaks, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Northridge Hospital Medical CenterNorthridge, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.11, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.147, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- UCLA West Valley Medical CenterWest Hills, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 1 of 5 · 53% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.454, Oct 2024 – Sep 2025
See every measure and the patient survey for Los Robles Hospital & Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 1 better, 7 the same, 0 worse of 8 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.84 (0 to 1.7) · 2,135 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.83 (0.56 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 194.58 (150.2 to 238.96) · 162 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 76 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 183 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.3 · 251 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 535 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 970 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 352 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,468 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.33) · 12,215 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.03 to 0.38) · 12,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3 (1.28 to 4.71) · 3,156 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.29 (0 to 2.81) · 1,553 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.74 (0.42 to 3.07) · 3,078 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.59 (6.22 to 16.96) · 1,658 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.29 (2.13 to 8.45) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.51 (0.09 to 2.92) · 825 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.1 (0 to 0.64) · 9,549 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 208 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.763 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.621 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.855 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.744 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 239 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 502 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.9 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -7.5 · 623 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31 · 1,042 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 939 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 197 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.3 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 213 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.7 to 17) · 361 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 718 cases | No different | Jan 2024 – Dec 2024 |
What patients said (682 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 65% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Northridge Hospital Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.11 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.147 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.13 (0.13 to 2.13) · 1,012 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.78 (0.44 to 1.11) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.43 (96.43 to 190.42) · 88 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 40 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 216 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 457 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.4 · 384 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 315 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 3,091 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.05 to 0.44) · 6,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 6,139 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,225 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.28 to 3.34) · 1,193 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.26 (0 to 15.07) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.14 (2.11 to 10.16) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.14) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.76) · 5,578 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 139 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 1.041 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 368 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 674 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 27.2 · 214 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.2 · 563 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.8 · 438 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17 · 484 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.1 to 7.4) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (6.8 to 13.8) · 44 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 166 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.9 · 57 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 141 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 165 cases | No different | Jan 2024 – Dec 2024 |
What patients said (621 patients answered, 15% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for UCLA West Valley Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.454 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.87 (0 to 1.86) · 925 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.74 to 1.41) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 126.11 (75.24 to 176.99) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 179 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 310 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.3 · 499 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 187 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.36) · 5,783 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.09 to 0.48) · 5,787 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.94 (1.81 to 6.06) · 1,083 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.83 (0.29 to 3.36) · 1,048 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.62 (6.73 to 22.51) · 354 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.07 (1.14 to 9) · 319 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 221 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1.09) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.457 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.124 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.781 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.838 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 201 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 400 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 5.5 · 173 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.2 · 369 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 51.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 569 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.8 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (9.3 to 17.4) · 30 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 136 cases | No different | Jan 2024 – Dec 2024 |
What patients said (519 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 67% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 64% |
| Doctors "always" treated them with courtesy and respect | 73% |
| Patients who gave a rating of "9" or "10" (high) | 52% |
| Staff "always" explained new medications | 64% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 74% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 53% |
| Staff "always" explained possible side effects | 35% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
Original Medicare doctor bills
$353,639
Medicare paid this office $353,639 for 700 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 520 | $165,628 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 348 | $58,087 | $142 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 30 | $39,241 | $293 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 26 | $16,900 | $245 |
| Critical care, first 30-74 minutes | 28 | $15,631 | $172 |
See all 16 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 520 | $165,628 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 348 | $58,087 | $142 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 30 | $39,241 | $293 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 26 | $16,900 | $245 |
| Critical care, first 30-74 minutes | 28 | $15,631 | $172 |
| Return visit (30+ min) | 62 | $11,709 | $110 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 22 | $6,422 | $34 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 24 | $6,078 | $43 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $5,951 | $65 |
| Long return visit (40+ min) | 30 | $5,886 | $155 |
| New patient visit (60+ min) | 19 | $3,382 | $178 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 18 | $2,997 | $44 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 83 | $2,560 | $14 |
| New patient visit (45+ min) | 18 | $2,418 | $134 |
| Dialysis services, 1 physician visit per month (20 years or older) | 11 | $2,385 | $170 |
| Complete ultrasound scan behind abdominal cavity | 11 | $998 | $91 |
Who their Medicare patients are
700 Original Medicare patients in 2024. Average age 78 · Under 65 9% · 85 and older 30% · Women 49% · Also on Medicaid 58% · Health risk score 3.84. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Coronary heart disease 74% · Diabetes 70% · Heart failure 70% · Depression 50% · Atrial fibrillation 48% · COPD 41% · Dementia 36% · Stroke 27% · Cancer 24%.
The office billed $903,210, Medicare allowed $445,052 and paid $353,639; for 3,421 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 700 | 3,421 | 78 | 3.84 | $903,210 | $353,639 |
| 2023 | 283 | 1,649 | 75 | 4.73 | $533,638 | $176,086 |
| 2022 | 235 | 1,509 | 73 | 3.77 | $452,945 | $152,828 |
| 2021 | 235 | 1,399 | 73 | 4.43 | $426,145 | $139,110 |
| 2020 | 231 | 1,357 | 73 | 4.52 | $395,540 | $130,541 |
| 2019 | 260 | 1,705 | 74 | 4.69 | $473,215 | $144,895 |
| 2018 | 303 | 1,872 | 74 | 4.73 | $448,415 | $139,682 |
| 2017 | 170 | 869 | 75 | 4.48 | $212,150 | $63,472 |
| 2014 | 59 | 190 | 73 | 2.75 | $57,153 | $16,869 |
| 2013 | 143 | 504 | 72 | 2.36 | $144,310 | $40,396 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 196 | $88,845 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 171 | $28,282 | $141 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 25 | $18,694 | $237 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 11 | $9,823 | $298 |
| Hemodialysis procedure with physician evaluation | 35 | $8,507 | $57 |
| Return visit (30+ min) | 30 | $5,835 | $90 |
| Hospital discharge day management, 30 minutes or less | 48 | $3,959 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $3,778 | $66 |
2022: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 164 | $67,389 | $82 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 19 | $32,711 | $242 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 122 | $24,308 | $159 |
| Return visit (30+ min) | 34 | $8,924 | $100 |
| Hemodialysis procedure with physician evaluation | 38 | $8,717 | $59 |
| Hospital discharge day management, 30 minutes or less | 86 | $6,233 | $58 |
| New patient visit (45+ min) | 19 | $2,361 | $124 |
2021: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 164 | $61,024 | $84 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 16 | $26,329 | $244 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 110 | $21,657 | $160 |
| Hemodialysis procedure with physician evaluation | 49 | $12,962 | $59 |
| Return visit (30+ min) | 34 | $6,477 | $100 |
| Hospital discharge day management, 30 minutes or less | 78 | $5,623 | $59 |
| New patient visit (45+ min) | 20 | $2,528 | $126 |
2020: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 171 | $65,777 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 110 | $21,705 | $166 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 11 | $17,724 | $199 |
| Hemodialysis procedure with physician evaluation | 48 | $11,297 | $60 |
| Hospital discharge day management, 30 minutes or less | 67 | $4,905 | $61 |
| Return visit (30+ min) | 25 | $4,846 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,790 | $112 |
2019: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 182 | $58,520 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 107 | $21,501 | $163 |
| Hemodialysis procedure with physician evaluation | 57 | $18,476 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 98 | $14,938 | $59 |
| Return visit (30+ min) | 33 | $6,462 | $83 |
| Hospital discharge day management, 30 minutes or less | 66 | $5,763 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 39 | $5,503 | $110 |
| New patient visit (30+ min) | 15 | $1,061 | $71 |
2018: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 176 | $43,534 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 218 | $36,990 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 115 | $21,463 | $164 |
| Hemodialysis procedure with physician evaluation | 70 | $18,648 | $59 |
| Hospital discharge day management, 30 minutes or less | 85 | $6,861 | $60 |
| Return visit (30+ min) | 24 | $5,550 | $84 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,741 | $110 |
| New patient visit (30+ min) | 15 | $1,340 | $89 |
2017: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 111 | $23,036 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $10,451 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,144 | $164 |
| Hemodialysis procedure with physician evaluation | 46 | $9,010 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $4,083 | $110 |
| Hospital discharge day management, 30 minutes or less | 59 | $3,900 | $59 |
2014: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,260 | $87 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,727 | $115 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,623 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,447 | $60 |
2013: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $11,585 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 58 | $7,435 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 45 | $5,211 | $111 |
| Hospital discharge day management, 30 minutes or less | 52 | $3,136 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,118 | $164 |
| Hospital discharge day management, more than 30 minutes | 31 | $2,716 | $88 |
| Initial hospital observation care per day, typically 50 minutes | 12 | $1,419 | $109 |
| Hospital observation care on day of discharge | 15 | $887 | $59 |
Medicaid work
$18,279 in 2024
Medicaid paid $18,279 for 806 billed services this clinician did in 2024, up to 37 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 647 | $12,340 |
| 1ST HOSP IP/OBS HIGH 75 | 159 | $5,939 |
| 2024 | 806 | 2 | 37 | $18,279 |
| 2023 | 1,422 | 7 | 39 | $40,571 |
| 2022 | 3,337 | 8 | 54 | $119,073 |
| 2021 | 2,599 | 9 | 45 | $88,656 |
| 2020 | 1,947 | 6 | 50 | $70,900 |
| 2019 | 2,705 | 7 | 50 | $79,443 |
| 2018 | 2,617 | 7 | 52 | $64,259 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 817 | $16,921 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 94 | $7,203 |
| 1ST HOSP IP/OBS HIGH 75 | 140 | $6,971 |
| Return visit (30+ min) | 262 | $6,837 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 41 | $1,469 |
| New patient visit (45+ min) | 16 | $620 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 52 | $551 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,438 | $45,606 |
| 1ST HOSP IP/OBS HIGH 75 | 312 | $20,700 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 191 | $19,171 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 106 | $13,022 |
| Return visit (30+ min) | 333 | $8,877 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 344 | $5,517 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 586 | $5,213 |
| New patient visit (45+ min) | 27 | $965 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,204 | $37,782 |
| 1ST HOSP IP/OBS HIGH 75 | 302 | $19,920 |
| Return visit (30+ min) | 234 | $6,912 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 339 | $6,405 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 415 | $5,472 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 20 | $5,250 |
| End-stage renal disease (ESRD) related services monthly, for patients 20 years of age and older; with 2-3 face-to-face visits by a physician or other qualified health care professional per month | 42 | $4,733 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 31 | $1,624 |
| New patient visit (45+ min) | 12 | $558 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,040 | $32,014 |
| 1ST HOSP IP/OBS HIGH 75 | 283 | $25,075 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 272 | $6,637 |
| Return visit (30+ min) | 145 | $4,255 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 191 | $1,837 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 16 | $1,082 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 1,139 | $28,247 |
| 1ST HOSP IP/OBS HIGH 75 | 386 | $27,947 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 531 | $7,493 |
| Return visit (30+ min) | 237 | $6,703 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 352 | $4,997 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 29 | $3,679 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 31 | $377 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,033 | $20,204 |
| 1ST HOSP IP/OBS HIGH 75 | 300 | $18,091 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 734 | $16,704 |
| Hospital inpatient or observation discharge day management; 30 minutes or less on the date of the encounter | 284 | $3,481 |
| Return visit (30+ min) | 136 | $3,407 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 15 | $1,475 |
| Hemodialysis procedure with single evaluation by a physician or other qualified health care professional | 115 | $898 |
Drugs they prescribed that Part D paid
$280,987
Pharmacies billed $280,987 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,063) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
793 generic and 270 brand-name prescriptions · $280,987 in drug cost · 46 antibiotic prescriptions to 35 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Kerendia | 54 | $58,593 | $1,085 |
| Farxiga | 34 | $40,740 | $1,198 |
| Veltassa | 57 | $38,486 | $675 |
| Tolvaptan | 16 | $26,224 | $1,639 |
| Jardiance | 16 | $22,732 | $1,421 |
See all 27 drugs
| Kerendia | 54 | $58,593 | $1,085 |
| Farxiga | 34 | $40,740 | $1,198 |
| Veltassa | 57 | $38,486 | $675 |
| Tolvaptan | 16 | $26,224 | $1,639 |
| Jardiance | 16 | $22,732 | $1,421 |
| Potassium Citrate Er | 16 | $5,025 | $314 |
| Retacrit | 11 | $1,979 | $180 |
| Losartan | 77 | $1,705 | $22 |
| Nifedipine Er | 47 | $1,308 | $28 |
| Bumetanide | 41 | $1,247 | $30 |
| Amlodipine Besylate | 55 | $476 | $9 |
| Lisinopril | 65 | $394 | $6 |
| Tamsulosin | 21 | $392 | $19 |
| Furosemide | 83 | $336 | $4 |
| Calcitriol | 12 | $332 | $28 |
| Hydralazine | 23 | $304 | $13 |
| Allopurinol | 45 | $302 | $7 |
| Valsartan | 14 | $243 | $17 |
| Chlorthalidone | 15 | $210 | $14 |
| Olmesartan Medoxomil | 16 | $201 | $13 |
| Benazepril | 20 | $164 | $8 |
| Klor-Con 8 | 13 | $161 | $12 |
| Spironolactone | 11 | $135 | $12 |
| Ciprofloxacin | 33 | $104 | $3 |
| Hydrochlorothiazide | 20 | $81 | $4 |
| Carvedilol | 11 | $44 | $4 |
| Irbesartan | 14 | $39 | $3 |
Year by year
| 2024 | 1,063 | 200 | 0% (0) | 25% | $280,987 |
| 2023 | 485 | 121 | None | None | $87,582 |
| 2022 | 506 | 120 | None | None | $85,033 |
| 2021 | 400 | 85 | None | None | $20,535 |
| 2020 | 298 | 72 | None | 13% | $13,096 |
| 2019 | 274 | 75 | None | None | $16,745 |
| 2018 | 259 | 69 | None | None | $19,049 |
| 2017 | 122 | 49 | None | 11% | $5,849 |
| 2016 | 110 | 21 | 0% (0) | None | $8,856 |
| 2015 | 118 | 20 | 0% (0) | None | $3,579 |
| 2014 | 132 | 48 | None | 17% | $5,779 |
| 2013 | 208 | 95 | 6% (12) | None | $6,263 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Kerendia | 18 | $14,774 | $821 |
| Clinolipid | 29 | $7,771 | $268 |
| Potassium Chloride | 11 | $1,694 | $154 |
| Calcium Acetate | 15 | $1,294 | $86 |
| Losartan | 25 | $848 | $34 |
| Nifedipine Er | 15 | $346 | $23 |
| Amlodipine Besylate | 25 | $298 | $12 |
| Pantoprazole | 13 | $291 | $22 |
| Tamsulosin | 11 | $247 | $22 |
| Lisinopril | 15 | $215 | $14 |
| Furosemide | 34 | $149 | $4 |
| Clopidogrel | 14 | $143 | $10 |
| Atorvastatin | 13 | $134 | $10 |
| Hydralazine | 16 | $118 | $7 |
2022: 13 drugs
| Sevelamer Carbonate | 16 | $24,271 | $1,517 |
| Calcium Acetate | 21 | $2,627 | $125 |
| Olmesartan Medoxomil | 13 | $586 | $45 |
| Losartan | 47 | $364 | $8 |
| Hydralazine | 23 | $293 | $13 |
| Atorvastatin | 22 | $153 | $7 |
| Lisinopril | 11 | $139 | $13 |
| Amlodipine Besylate | 31 | $114 | $4 |
| Furosemide | 27 | $110 | $4 |
| Pantoprazole | 14 | $89 | $6 |
| Carvedilol | 11 | $78 | $7 |
| Benazepril | 16 | $72 | $4 |
| Clopidogrel | 12 | $49 | $4 |
2021: 9 drugs
| Calcium Acetate | 11 | $404 | $37 |
| Hydralazine | 31 | $333 | $11 |
| Tamsulosin | 22 | $278 | $13 |
| Amlodipine Besylate | 25 | $150 | $6 |
| Atorvastatin | 15 | $145 | $10 |
| Allopurinol | 11 | $124 | $11 |
| Losartan | 27 | $115 | $4 |
| Furosemide | 22 | $109 | $5 |
| Benazepril | 18 | $71 | $4 |
2020: 6 drugs
| Tamsulosin | 15 | $253 | $17 |
| Losartan | 33 | $214 | $6 |
| Lisinopril | 16 | $131 | $8 |
| Amlodipine Besylate | 18 | $80 | $4 |
| Furosemide | 23 | $64 | $3 |
| Metoprolol | 11 | $22 | $2 |
2019: 5 drugs
| Losartan | 46 | $313 | $7 |
| Tamsulosin | 14 | $228 | $16 |
| Lisinopril | 14 | $98 | $7 |
| Furosemide | 18 | $54 | $3 |
| Ciprofloxacin | 11 | $33 | $3 |
2018: 6 drugs
| Tamsulosin | 22 | $278 | $13 |
| Benazepril | 12 | $76 | $6 |
| Pantoprazole | 12 | $67 | $6 |
| Losartan | 17 | $63 | $4 |
| Ciprofloxacin | 11 | $53 | $5 |
| Furosemide | 15 | $37 | $2 |
2016: 1 drug
| Nifedipine Er | 12 | $1,024 | $85 |
2015: 2 drugs
| Tamsulosin | 15 | $715 | $48 |
| Nifedipine Er | 13 | $356 | $27 |
2014: 1 drug
| Ciprofloxacin | 11 | $61 | $6 |
2013: 4 drugs
| Clopidogrel | 11 | $254 | $23 |
| Levofloxacin | 18 | $138 | $8 |
| Simvastatin | 11 | $88 | $8 |
| Lisinopril | 12 | $64 | $5 |
Money from drug and device companies
$1,172 in 2025
| 2025 | 12 | 59 | None | $1,172 |
| 2024 | 16 | 51 | None | $1,313 |
| 2023 | 12 | 24 | None | $514 |
| 2022 | 5 | 15 | None | $354 |
| 2021 | 3 | 6 | None | $103 |
| 2020 | 3 | 9 | None | $166 |
| 2019 | 2 | 2 | None | $38 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Krystexxa | $330 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $220 | 9 payments
|
| Novartis Pharmaceuticals | Leqvio | $164 | 5 payments
|
| Lilly USA | Jardiance | $91 | 4 payments
|
| Otsuka America Pharmaceutical | Jynarque | $72 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $61 | 3 payments
|
See all 50 published payments
| Otsuka America Pharmaceutical | Meals · 2025-12-09 | Jynarque | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-06 | Farxiga | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-20 | Farxiga | $31 |
| Akebia Therapeutics | Meals · 2025-11-18 | Auryxia | $28 |
| Calliditas Therapeutics US | Meals · 2025-11-17 | Tarpeyo | $23 |
| Amgen | Meals · 2025-11-11 | Repatha | $22 |
| Amgen | Meals · 2025-11-03 | Krystexxa | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-28 | Jardiance | $18 |
| Novartis Pharmaceuticals | Meals · 2025-10-23 | Leqvio | $35 |
| Amgen | Meals · 2025-10-14 | Tavneos | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-07 | Kerendia | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | Farxiga | $25 |
| Amgen | Meals · 2025-09-09 | Krystexxa | $20 |
| Lilly USA | Meals · 2025-08-29 | Jardiance | $28 |
| Novartis Pharmaceuticals | Meals · 2025-08-26 | None | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-21 | Farxiga | $14 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-05 | Jardiance | $29 |
| Novartis Pharmaceuticals | Meals · 2025-08-04 | None | $35 |
| Amgen | Meals · 2025-07-29 | Tavneos | $22 |
| Amgen | Meals · 2025-07-28 | Krystexxa | $20 |
| Amgen | Meals · 2025-07-24 | Krystexxa | $28 |
| Lilly USA | Meals · 2025-07-14 | Jardiance | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-02 | Farxiga | $25 |
| Akebia Therapeutics | Meals · 2025-06-24 | Auryxia | $27 |
| Travere Therapeutics | Meals · 2025-06-13 | None | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-10 | Farxiga | $22 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-03 | Kerendia | $19 |
| Amgen | Meals · 2025-05-28 | Krystexxa | $9 |
| Amgen | Meals · 2025-05-27 | Krystexxa | $22 |
| Otsuka America Pharmaceutical | Meals · 2025-05-20 | Jynarque | $26 |
| Amgen | Meals · 2025-05-06 | Krystexxa | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-30 | Kerendia | $19 |
| GlaxoSmithKline | Meals · 2025-04-28 | Benlysta | $31 |
| Aurinia Pharma U.S. | Meals · 2025-04-22 | Lupkynis | $22 |
| Lilly USA | Meals · 2025-04-21 | Jardiance | $21 |
| Amgen | Meals · 2025-04-21 | Tavneos | $8 |
| Lilly USA | Meals · 2025-04-17 | Jardiance | $27 |
| Novartis Pharmaceuticals | Meals · 2025-04-14 | None | $29 |
| Otsuka America Pharmaceutical | Meals · 2025-04-07 | Jynarque | $29 |
| Amgen | Meals · 2025-03-25 | Krystexxa | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-18 | Farxiga | $21 |
| Amgen | Meals · 2025-03-03 | Tavneos | $10 |
| Travere Therapeutics | Meals · 2025-02-21 | None | $27 |
| Amgen | Meals · 2025-02-17 | Krystexxa | $32 |
| Amgen | Meals · 2025-02-11 | Repatha | $28 |
| Amgen | Meals · 2025-02-07 | Krystexxa | $8 |
| Amgen | Meals · 2025-01-30 | Krystexxa | $7 |
| Novartis Pharmaceuticals | Meals · 2025-01-27 | None | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-22 | Farxiga | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-22 | Farxiga | $28 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,313
| Amgen | Krystexxa | $481 | 20 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $210 | 5 payments
|
| Lilly USA | Mounjaro | $83 | 3 payments
|
| Otsuka America Pharmaceutical | Jynarque | $75 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $68 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $66 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $49 | 2 payments
|
| OPKO Pharmaceuticals | Rayaldee | $48 | 2 payments
|
| Calliditas Therapeutics US | Tarpeyo | $47 | 2 payments
|
| Akebia Therapeutics | Auryxia | $43 | 2 payments
|
| Novartis Pharmaceuticals | None | $31 | 1 payment
|
| GlaxoSmithKline | Benlysta | $26 | 1 payment
|
| Vifor Pharma | Veltassa | $25 | 1 payment
|
| Novo Nordisk | Ozempic | $23 | 1 payment
|
| Daiichi Sankyo | Injectafer | $21 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $16 | 1 payment
|
2023: $514
| GlaxoSmithKline | Jesduvroq | $152 | 8 payments
|
| Amgen | Epogen | $59 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $50 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $48 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $38 | 2 payments
|
| Travere Therapeutics | None | $28 | 1 payment
|
| Horizon Therapeutics plc | None | $26 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $25 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $24 | 1 payment
|
| Fresenius USA Marketing | None | $24 | 1 payment
|
| Vifor Pharma | Veltassa | $21 | 1 payment
|
| Calliditas Therapeutics US | Tarpeyo | $17 | 1 payment
|
2022: $354
| AstraZeneca Pharmaceuticals LP | Lokelma | $131 | 6 payments
|
| GlaxoSmithKline | Benlysta | $96 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $92 | 4 payments
|
| Philips Electronics North America | (7999) Src Und | $20 | 1 payment
|
| Horizon Therapeutics plc | Krystexxa | $15 | 1 payment
|
2021: $103
| AstraZeneca Pharmaceuticals LP | Lokelma | $49 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $37 | 2 payments
|
| Amgen | Parsabiv | $16 | 1 payment
|
2020: $166
| AstraZeneca Pharmaceuticals LP | Lokelma | $80 | 5 payments
|
| Amgen | Parsabiv | $66 | 3 payments
|
| Relypsa | Veltassa | $20 | 1 payment
|
2019: $38
| Relypsa | Veltassa | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $19 | 1 payment
|
Professional record
- NPI
- 1215241740
- Licence
- CA A112947California A112947: Current · expires 2028-04-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 18433 Roscoe Blvd Ste 106, Northridge, CA, 91325
- NPI first listed
- 2010-07-26
- NPI last updated
- 2023-12-01
- NPI record certified
- 2023-12-01
This is when the NPI record was last certified, not a medical board exam.